Breaking Finance News

Bryan Garnier issued a report on AstraZeneca PLC (LON:AZN), retaining its target price at 5,220.00GBX today

Having a price of 4,919.50GBX, AstraZeneca PLC (LON:AZN) traded -1.22% lower on the day. With the last close up 9.24% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. AZN has recorded a 50-day average of 4,994.73GBX and a two hundred day average of 4,473.20GBX. Trade Volume was down over the average, with 610,460 shares of AZN changing hands under the typical 2,541,030

AstraZeneca PLC (LON:AZN) had its target price hold steady to 5,220.00GBX by Bryan Garnier in a report released 10/17/2016. The updated stock price target implies a possible upside of 0.06% from the company's previous close.

On 10/13/2016, Jefferies International released a statement on AstraZeneca PLC (LON:AZN) upped the target price from 5,800.00GBX to 6,000.00GBX that suggested an upside of 0.20%.

Recent Performance Chart

AstraZeneca PLC (LON:AZN)

AstraZeneca PLC has P/E ratio of 27.92 with a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX and has a market cap of 0 GBX.

In addition to Bryan Garnier reporting its target price, a total of 29 firms have issued a report on the stock. The consensus target price is 61.96GBX with 4 firms rating the stock a strong buy, 14 firms rating the stock a buy, 13 firms rating the stock a hold, 2 firms rating the stock a underperform, and finally 1 firm rating the stock a sell.

About AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.